Enhancement of Osteogenic Induction by LL37 Modified With Collagen Binding Domain in Vitro and in Vivo
Bone defect diseases, particularly induced by inflammation, render a challenge for designing ideal drug-loading scaffold that could facilitate bone repairing and eliminate inflammatory pathogens. LL37 is considered as promising alternative loading drug due to its broad-spectrum antimicrobial effect and various bio-functions including osteogenic induction. In this study, we synthesized modified LL37 by adding collagen binding domain (CBD), which aim to provide a specific binding onto collagen and slow-releasing pattern. The modified peptide was proved to exhibit similar biological activities to nature LL37 on rat BMSCs including promoting migration activity, anti-inflammatory activity and osteogenic induction in vitro. Ectopic bone formation experiment further confirmed the angiogenesis and osteoinduction activities in vivo. Collectively, LL37-CBD may be a potential loaded drug for preventative and curative applications in Inflammation-induced bone diseases, exerting dual strategies including anti-inflammatory and osteogenic effects.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Due to technical limitations, full-text HTML conversion of this manuscript could not be completed. However, the manuscript can be downloaded and accessed as a PDF.
Posted 22 Dec, 2020
Received 12 Jan, 2021
On 11 Jan, 2021
On 05 Jan, 2021
Invitations sent on 03 Jan, 2021
On 13 Dec, 2020
On 13 Dec, 2020
On 13 Dec, 2020
On 10 Dec, 2020
Enhancement of Osteogenic Induction by LL37 Modified With Collagen Binding Domain in Vitro and in Vivo
Posted 22 Dec, 2020
Received 12 Jan, 2021
On 11 Jan, 2021
On 05 Jan, 2021
Invitations sent on 03 Jan, 2021
On 13 Dec, 2020
On 13 Dec, 2020
On 13 Dec, 2020
On 10 Dec, 2020
Bone defect diseases, particularly induced by inflammation, render a challenge for designing ideal drug-loading scaffold that could facilitate bone repairing and eliminate inflammatory pathogens. LL37 is considered as promising alternative loading drug due to its broad-spectrum antimicrobial effect and various bio-functions including osteogenic induction. In this study, we synthesized modified LL37 by adding collagen binding domain (CBD), which aim to provide a specific binding onto collagen and slow-releasing pattern. The modified peptide was proved to exhibit similar biological activities to nature LL37 on rat BMSCs including promoting migration activity, anti-inflammatory activity and osteogenic induction in vitro. Ectopic bone formation experiment further confirmed the angiogenesis and osteoinduction activities in vivo. Collectively, LL37-CBD may be a potential loaded drug for preventative and curative applications in Inflammation-induced bone diseases, exerting dual strategies including anti-inflammatory and osteogenic effects.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Due to technical limitations, full-text HTML conversion of this manuscript could not be completed. However, the manuscript can be downloaded and accessed as a PDF.